Guangzhou Innogen Pharmaceutical Group Co Ltd (hkse:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
96

Recommended

The stocks of these high-quality companies with large market capitalizations look undervalued today.

Margaret Giles | 02 February 2026

Prices of these shares exceed our Fair Value Estimate by more than double.

Morningstar | 02 February 2026

Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.

Robert M. Almeida | 02 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,068.80	42.20	-0.46%
CAC 40	8,187.24	60.71	0.75%
DAX 40	24,798.53	259.72	1.06%
Dow JONES (US)	49,245.55	353.08	0.72%
FTSE 100	10,314.85	91.31	0.89%
HKSE	26,775.57	611.54	-2.23%
NASDAQ	23,609.62	147.80	0.63%
Nikkei 225	52,655.18	667.67	-1.25%
NZX 50 Index	13,412.44	10.74	-0.08%
S&P 500	6,971.07	32.04	0.46%
S&P/ASX 200	8,778.60	42.50	-0.48%
SSE Composite Index	4,015.75	102.20	-2.48%